FTC Says Ex‑‘Pharma Bro’ Breached Lifetime Bar by Trading Drug Stocks

The Federal Trade Commission lodged a complaint asserting that Martin Shkreli, the ex‑pharmaceutical executive infamous for his contentious pricing tactics, has been purchasing and disposing of shares in firms that create or sell medicines, an activity that may breach his lifetime industry ban.

Shkreli, dubbed “Pharma Bro” after a widely publicized incident concerning the price hike of the antiparasitic drug Daraprim, was permanently barred by the FTC years earlier after the agency concluded he had participated in unlawful marketing and related wrongdoing.

According to the latest FTC filing, Shkreli has remained active in the equities market despite the prohibition, carrying out trades across multiple pharmaceutical companies. The commission says it uncovered the behavior by examining trading logs that reveal repeated buys and sells of securities tied to drug development and distribution.

Regulators explain that the ban was designed to keep Shkreli from shaping the pharmaceutical arena, and any violation erodes the FTC’s enforcement power. Breaching a lifetime prohibition could subject him to civil fines, injunctions and potentially additional criminal referrals.

Legal analysts point out that the FTC may pursue monetary penalties and an order prohibiting Shkreli from any future participation in pharma‑related securities. The agency could also forward the case to the Department of Justice should it deem criminal conduct present.

So far, Shkreli has offered no public comment on the accusations, and his lawyers have signaled plans to challenge the commission’s allegations.

The lawsuit underscores the difficulties regulators encounter in overseeing adherence to long‑term bans, particularly when individuals use financial markets to retain influence.

Watchers will be attentive to the upcoming court hearing on the FTC’s complaint, which may establish precedent for the vigor with which lifetime bans are applied in biotech and pharmaceutical sectors.